Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

News

Graphic highlighting the liver in the human body, overlayed with data from the publication showing the established human MASLD trajectory based on patient transcriptomic data.

Molecular map of liver disease could transform how MASLD is diagnosed and monitored

14 July 2026

A new study establishes a molecular map of disease progression in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), and identifies a set of blood biomarkers that could improve diagnosis.

Summary

  • Scientists mapped the molecular progression of MASLD, uncovering how biological processes driving liver damage change over time, creating a framework for more precise stage-specific therapies.
  • They identified a blood...

    Read more

Read more news about Open Targets

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Our scientific approach
Open Exchange of Ideas

We are committed to making our data, methods and results publicly available as soon as possible to foster an open exchange of ideas

Our latest publications
Multidisciplinary collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Our partners and collaborators

Blog

Bluesky